Poniard Pharmaceuticals, Inc. (PARD)

[DeadCellShadix]

Good number!

[The_Shadow]

got 18k worth :)

[DeadCellShadix]

This is gonna get really pretty here in a bit... it's setting up very nicely..

[DeadCellShadix]

Amen. I couldnt have said it better. Not to mention, they live off the government "the one they dont have" and the taxes taken out of our paychecks. A buncha rednecks if you ask me. Nice Flip! Dont chase!

[sherwood37]

lol you might not get 0.25 or even 0.28 if they look like Parisara i would love to go there. nice eyes and lips. i hope you mede money thats all that matters Parisasa! GLTY Lol fat and uneducated lol. you played this good you may get 0.25

[Parisara]

...and they are ugly, fat, stupid, uneducated..i dont like them.

[Parisara]

i sold, will buy back @0.25 now for sure!

[DeadCellShadix]

Im not a huge fan of Belgium... a buncha grumpy people here in Mons. They dont like us Americano type too much.

[sherwood37]

im green i know that!

[Parisara]

ow belgium.... nice country..but france rules!

[DeadCellShadix]

Nice bids @ .29 she has her legs, time to make some moneys.

[DeadCellShadix]

Nice poise, you have more than I.. Im just not too attached to my moneys so I tend to throw it wherever, sometimes it works out for me and others it doesnt.. either way, I know when to get out From france eh? Im in Belgium right now ><

[sherwood37]

iv got 10k at 0.28

[Parisara]

ow cool!

i like all you people that bought higher then me..:)

[DeadCellShadix]

got me 18k worth :D

[sherwood37]

me to but it only a few tics no biggie

[DeadCellShadix]

Well, you needed a starter position somewhere... this is why the sophisticated investor never goes all-in at one PPS. I however, am not sophisticated and .3 sounded good to me

[Parisara]

.... i always buy to high lol

thanks though...

look its moving up! :)

[sherwood37]

im not worried a bit just some taking 100% profit youll have that

[DeadCellShadix]

Look at it this way, you bought at .28, what about all them peoples who bought at .39? Eeep. Im sure we will all benefit in the coming days, if not today ~_^

[Parisara]

good, makes me feel better!

lets see if it gets op in the 0.30s again.

[Parisara]

ow man, this starts to scare me!

[Parisara]

ow man, this starts to scare me!

[sherwood37]

it will bounce im holding till lunch

[sherwood37]

i bought 0.28 to

[Parisara]

looks like it wants to go down from here..................

[sherwood37]

MMs will play with it the first hour. then by lunch time it will run hard they always run big before lunch.

[sherwood37]

going back up

[Parisara]

yes 0.40!!

buy buy buy

[sherwood37]

youll be ok.

[Parisara]

true, but risk and stupidity are sometimes very close!


shi.t bought it @0.28

[sherwood37]

0.40 today!

[DeadCellShadix]

We do have a looong trading day to go..

[sherwood37]

you might get it. Is that profile pic you? Wow very pretty! Not hitting one you i just was shocked at you pic beautiful!

[DeadCellShadix]

People who never takes risks, never get reward :-/ that's my philosophy.

[Parisara]

i want it,.. but its so dangerous to buy it this high!

[sherwood37]

you might get it.

[Parisara]

how high you think it will go?

[Parisara]

yeah.. would love to have it @0.25

[sherwood37]

Parisara this one will run hard till about 1:00 central time USA. But wait for a pullback! Great news!

[DeadCellShadix]

Hmmm im comfortable with my .3 position, add on the dips

[Parisara]

massive uptick indeed.,... what price should one get in?

[I Love Roth Iras]

nice gap up today..was in this year ago when it was NERX and shot up to $60.

[mlkrborn]

Poniard Pharma: ISS Proxy Advisory Services recommends poniard shareholders vote 'for' Poniard's proposed merger with ALLOZYNE and reverse stock split (PARD) 0.12 : Co announced that ISS Proxy Advisory Services has recommended that Poniard shareholders vote for all proposals listed in the Company's proxy materials, including the proposal to approve the issuance of common stock in connection with Poniard's proposed merger with ALLOZYNE, and the proposal to effect a 1-for-40 reverse stock split of Poniard's outstanding common stock.

[chartman2000]

I'm in...eom

[mlkrborn]

PARD 0.14; merging if approved and R/S 40 shares into 1.
Poniard Pharma: Egan-Jones recommends Poniard shareholders vote 'for' Poniard's proposed merger With Allozyne and reverse stock split (PARD) 0.14 +0.01 : Co announced today that Egan-Jones Proxy Services, an independent proxy advisory firm, has recommended that Poniard shareholders vote "for" all proposals listed in the Company's proxy statement materials, including the proposal related to the issuance of stock in connection with its proposed merger with Allozyne and the proposal to effect a reverse stock split of Poniard's outstanding common stock at a ratio of 1-for-40.

[surf1944]

7-Sep-2011

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

On September 6, 2011, the Company issued a press release announcing that the Nasdaq Listing Qualifications Hearings Panel granted the Company's request for continued listing of its common stock on The Nasdaq Capital Market, subject to satisfaction of certain conditions by December 31, 2011, including implementation of a reverse stock split sufficient to allow the stock to trade above $4.00, completion of the Company's planned merger with Allozyne, Inc. and approval from Nasdaq of the combined entity's application for initial listing on The Nasdaq Capital Market upon completion of the merger.

A copy of the Company's press release is attached hereto as Exhibit 99.1 and incorporated herein by reference, specifically including the cautionary note regarding forward-looking statements contained in the press release.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 - Press release dated September 6, 2011

[cgttrader]

Any news of the merger front...I know they didnt have enough votes for reverse split approval. I think they are going to put it up for a vote again. My issue is that if they do not get reverse split then they will continue to fall until they become completely delisted and no more. Thus the merger with Allozyne will fall through. I wonder why people are voting against the reverse split? Any thoughts?

[surf1944]

Poniard Pharmaceuticals Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With ALLOZYNE
Company to Seek Shareholder Approval of Merger, Reverse Stock Split; Pending Appeal, Company Received Notice of Delisting From The Nasdaq Capital Market

Press Release Source: Poniard Pharmaceuticals On Monday July 25, 2011, 5:38 pm EDT

SAN FRANCISCO, CA--(Marketwire - 07/25/11) - Poniard Pharmaceuticals, Inc. (NASDAQ:PARD - News) announced today that it has filed a Form S-4 Registration Statement with the U.S. Securities and Exchange Commission ("SEC") relating to its proposed merger with ALLOZYNE, Inc., a privately held biotechnology company focused on the development of bioconjugated protein therapeutics. The definitive merger agreement was entered into on June 22, 2011. The boards of directors of both companies have approved the merger transaction, which is subject to customary closing conditions, including approval by ALLOZYNE's and Poniard's respective stockholders and receipt of approval for listing of the combined company's common stock on The Nasdaq Capital Market.

"We believe that the proposed merger of Poniard and ALLOZYNE will create a robust company with a multifaceted strategy and presents a unique opportunity for creating long-term value for our shareholders," said Ronald A. Martell, Chief Executive Officer of Poniard. "With shareholder support for the merger and the necessary reverse split of Poniard's common stock, we anticipate closing of the transaction during the second half of 2011."

In addition to registering the shares of Poniard common stock to be issued to the stockholders of ALLOZYNE in the merger, the Registration Statement contains proxy materials for a special meeting of Poniard shareholders. At that meeting, Poniard shareholders will be asked to approve the issuance of Poniard common stock and the resulting change of control of Poniard pursuant to the merger agreement and the amendment of Poniard's articles of incorporation to effect a reverse stock split of Poniard's issued common stock, at a ratio of 1-for-25. Poniard will need to implement the reverse stock split to obtain the listing of the combined company on The Nasdaq Capital Market, which is one of the conditions to the closing of the merger. Once the Registration Statement is declared effective by the SEC, Poniard expects to set a record date for shareholders entitled to notice of and to vote at the special meeting as well as a meeting date.

Poniard also announced today that on July 19, 2011, it received written notice from the Nasdaq Listing Qualifications Staff that the Company's common stock will be delisted from The Nasdaq Capital Market effective July 28, 2011, for failure to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company has requested an oral hearing before a Nasdaq Hearings Panel to appeal the determination and present a plan to regain compliance with all applicable listing requirements. The hearing request and hearing stay the delisting pending the Panel's decision. There can be no assurance that the Company's plan of compliance will be accepted by the Panel or that the appeal otherwise will be successful.

As previously announced, on July 20, 2010, the Nasdaq Staff notified the Company that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days and, as a result, did not comply with Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until January 18, 2011, to regain compliance with the minimum bid price requirement. On December 17, 2010, the Company transferred its common stock listing to The Nasdaq Capital Market and subsequently, on January 19, 2011, was afforded a second 180 calendar day compliance period, or until July 18, 2011. The Company has not regained compliance with the minimum bid price requirement.

As described in its definitive Proxy Statement filed with the SEC on April 27, 2011, Poniard recently sought shareholder approval of a proposal authorizing its Board of Directors to effect a reverse stock split. On July 22, 2011, the Company adjourned the annual meeting of shareholders with an insufficient number of returned proxies and "FOR" votes to approve the reverse stock split proposal. Of the Company's common shares outstanding and entitled to vote at the annual meeting, approximately 49.2 percent returned proxies. Among returned proxies, approximately 91.6 percent (representing approximately 29.1 million votes) voted in favor of the reverse stock split proposal. Approximately 0.9 percent of total shares abstained, and approximately 7.5 percent of total shares voted against the reverse stock split proposal. The affirmative vote of a majority of the Poniard shares outstanding and entitled to vote is required to approve a reverse stock split under applicable law.

Important Additional Information

On July 25, 2011, Poniard filed a Registration Statement on Form S-4, which includes a preliminary proxy statement/prospectus/consent solicitation in connection with the merger. Once declared effective by the SEC, the definitive proxy statement/prospectus/consent solicitation included in the Form S-4 will be mailed to Poniard and ALLOZYNE shareholders. Investors and security holders of Poniard and ALLOZYNE are urged to read the definitive proxy statement/prospectus/consent solicitation, when it becomes available, because it will contain important information about Poniard, ALLOZYNE and the proposed transaction.

Investors and security holders of Poniard will be able to obtain free copies of the definitive proxy statement/prospectus/consent solicitation, when it becomes available, through the website maintained by the SEC at www.sec.gov. Free copies of the definitive proxy statement/prospectus/consent solicitation, when it becomes available, and Poniard's other filings with the SEC also may be obtained by contacting Poniard Pharmaceuticals, Inc., 750 Battery Street, Suite 330, San Francisco, CA 94111, or accessed via Poniard's website at www.poniard.com.

Poniard, and its respective directors and executive officers, may be deemed to be participants in the solicitation of proxies from its shareholders in favor of the proposed transaction. Information regarding the directors and executive officers of Poniard and their interests in the proposed transaction will be available in the definitive proxy statement/prospectus/information statement, when it becomes available.

[cgttrader]

$PARD Information from the Annual Shareholders Meeting last Friday should come out concerning the stock split. No news on Friday afternoon which is unusual right after the meeting. Decision must be made soon before stock is delisted from NASDAQ for averaging under $1 too long. Interesting in the results of the ALLOZYNE merger and what the stock price will do immediately after.